Form 4: Director Stephen Mayo Receives Sarepta Equity Grant

Sarepta Therapeutics director Stephen Mayo was granted 16,875 restricted stock units as part of standard equity compensation.

Summary

• Director Stephen Mayo acquired 16,875 restricted stock units (RSUs) of Sarepta Therapeutics common stock.
• The transaction occurred on June 4, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, the reporting person holds a total of 18,640 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine director compensation rather than a signal of operational performance or strategic shift.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant.

Risks

• None identified; this is a standard compensatory equity grant.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders occurring at least 50 weeks after the previous annual meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units is consistent with standard compensation packages for independent directors in the mid-to-large cap biopharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 16,875 RSUs upon the earlier of the one-year anniversary or the next annual meeting.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Equity Compensation, Director